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Abstract
Background: Few treatment options exist for patients with metastatic melanoma, resulting in poor prognosis. One
standard treatment, dacarbazine (DTIC), shows low response rates ranging from 15 to 25 percent with an 8-month
median survival time. The development of targeted therapeutics with novel mechanisms of action may improve
patient outcome. Ribosome-inactivating proteins (RIPs) such as Shiga-like Toxin 1 (SLT-1) represent powerful
scaffolds for developing selective anticancer agents. Here we report the discovery and properties of a single chain
ribosome-inactivating protein (scRIP) derived from the cytotoxic A subunit of SLT-1 (SLT-1A), harboring the 7-amino
acid peptide insertion IYSNKLM (termed SLT-1A
IYSNKLM) allowing the toxin variant to selectively target and kill
human melanoma cells.
Results: SLT-1A
IYSNKLM was able to kill 7 of 8 human melanoma cell lines. This scRIP binds to 518-A2 human
melanoma cells with a dissociation constant of 18 nM, resulting in the blockage of protein synthesis and apoptosis
in such cells. Biodistribution and imaging studies of radiolabeled SLT-1A
IYSNKLM administered intravenously into
SCID mice bearing a human melanoma xenograft indicate that SLT-1A
IYSNKLM readily accumulates at the tumor site
as opposed to non-target tissues. Furthermore, the co-administration of SLT-1A
IYSNKLM with DTIC resulted in tumor
regression and greatly increased survival in this mouse xenograft model in comparison to DTIC or SLT-1A
IYSNKLM
treatment alone (115 day median survival versus 46 and 47 days respectively; P values < 0.001). SLT-1A
IYSNKLM is
stable in serum and its intravenous administration resulted in modest immune responses following repeated
injections in CD1 mice.
Conclusions: These results demonstrate that the evolution of a scRIP template can lead to the discovery of novel
cancer cell-targeted compounds and in the case of SLT-1A
IYSNKLM can specifically kill human melanoma cells in vitro
and in vivo.
Background
The incidence of melanoma has been rising in the Uni-
ted States for the past sixty years [1,2]. Despite preven-
tion efforts, it remains the second leading cause of lost
productive years among all cancers, and is responsible
for more than 7,000 deaths annually [2]. Novel mela-
noma-targeted therapeutic agents are needed to improve
prognosis, since traditional treatments such as dacarba-
zine (DTIC) and IL-2 only yield a 5% survival advantage
of more than five years for patients with advanced mela-
noma [2]. Currently, targeted agents such as monoclonal
antibodies and recombinant proteins account for more
than a quarter of all cancer therapeutics that have been
newly approved or are presently in clinical trials [3,4].
Although effective in delaying the progression of certain
cancers, naked antibodies such as Herceptin and Avastin
do not cure the disease [5-7]. This limitation has led to
the use of tumor-targeted protein ligands in delivering
potent therapeutic cargoes such as radionuclides, drugs,
and protein toxins to tumor sites, bringing the overall
concept of personalized medicine closer to reality [3,4].
In particular, immunotoxins and protein toxin
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any medium, provided the original work is properly cited.conjugates have been the subject of clinical trials with a
fusion construct of IL-2 to diphtheria toxin (Ontak)
being approved by the FDA for the treatment of cuta-
neous T-cell lymphoma. Nevertheless, the use of toxin
conjugates as successful cancer therapeutics remains
limited [8-12]. To address some of the design challenges
facing targeted protein toxins, we created a combinator-
ial protein library based on the cytotoxic domain of a
protein toxin with a view to directly screen in cell-based
assays for variants bearing new ligand specificities and
able to selectively destroy cancer cells [13]. The
approach makes use of the cytotoxic A subunit of a bac-
terial ribosome-inactivating protein (RIP), namely Shiga-
like Toxin 1 (SLT-1), as a protein scaffold to design
anticancer agents. Specifically, the SLT-1 A subunit
encodes all functions necessary to route itself out of cel-
lular organelles in order to reach and inactivate ribo-
somes present in the cytoplasm of eukaryotic cells. This
event subsequently leads to apoptosis [14]. However, the
SLT-1 A subunit lacks the ability to target cancer cells.
In this report, we have inserted a random 7-amino acid
peptide motif into the structure of the SLT-1A domain
to create a combinatorial library of this protein template
expressing toxic SLT-1A mutants harboring a putative
peptide ligand that may specifically recognize, enter and
kill cancer cells (Figure 1). Searching through such a
library yielded a SLT-1A variant termed SLT-1A
IYSNKLM
that selectively targets human melanoma cell lines. The
mechanism of action and therapeutic activity of this sin-
gle chain ribosome-inactivating protein (scRIP) variant
closely parallel the predicted properties of a targeted
ribosome-inactivating protein, suggesting that RIP A
subunit libraries may represent a useful discovery tool
for targeted protein-based therapeutics. We have termed
this discovery approach RESCRIPT (Rapid Evolution
and Selection of Cancer-specific Ribosome-Inactivating
Protein Toxins) (see Additional File 1: Figure S1) which
is based on the identification of targeted RIPs with no a
priori knowledge of surface markers associated with can-
cer cells.
Results
Identification of SLT-1A
IYSNKLM: a human melanoma-
specific scRIP toxin variant
SLT-1 is a bacterial type II ribosome-inactivating pro-
tein produced by enteropathogenic E. coli strains such
as O157:H7. Previously, the full-length SLT-1 (70 kDa;
AB5) was used by our group as a scaffold to construct a
combinatorial library. Random peptide elements were
embedded within its receptor-binding B domain to alter
receptor-binding specificity, while the wild type cyto-
toxic A subunit was retained to screen the library for
SLT-1 variants able to selectively kill cancer cells [13].
However, the expression of protein variants from such a
library was typically less than 1% when mutations were
introduced in the receptor binding regions of the B sub-
unit. We therefore describe here a novel combinatorial
library designed using the smaller cytotoxic SLT-1 A
subunit (31 kDa) as a scaffold (Additional File 2).
A combinatorial SLT-1A protein library was con-
structed by inserting a random 7-amino acid peptide
element between residues 245 and 246 of the A subunit
(Figure 1A and Additional File 2). The insertion of this
heptapeptide did not affect the catalytic activity of SLT-
1A (Additional File 3). This peptide element was also
shown to be exposed on the surface of the A subunit
(Additional File 3). Single bacterial colonies were picked
from the library and led to the purification of 9,400 His-
tagged scRIP variants that were tested for their ability to
kill the wt SLT-1-resistant human melanoma cell line
518-A2 (see Additional File 1: Figure S1 and Additional
File 2). The initial screens led to the recovery of 112
SLT-1A toxin variants displaying cytotoxic profiles
towards cancer cell lines. These SLT-1A variants were
re-screened against 518-A2 cells, as well as against a
panel of twelve other cell lines (human unless otherwise
indicated): PC-3 (prostate cancer), SKBR-3 (breast can-
cer), CAMA-1 (breast cancer), U87 (glioma), OVCAR-3
(ovarian carcinoma), SiHa (cervical cancer), PanC (pan-
creatic cancer), B16-F10 (mouse melanoma), Vero
(monkey, normal kidney), HS-216 (normal fibroblast),
H-MEC (normal mammary epithelial cells), and H-REC
(normal kidney cells). This counter-selection step led to
the identification of an A subunit toxin variant, named
SLT-1A
IYSNKLM, harboring the peptide sequence
IYSNKLM, that selectively targets and kills 518-A2 cells
in a dose-dependent manner [CD50 ~300 nM] (Figure
2A). Furthermore, SLT-1A
IYSNKLM demonstrates broad
specificity towards melanoma cell lines, killing 7 of 8
human melanoma cell lines tested (518-A2, A-2058, A-
375, C-32, MALME-3 M, MeWo, SK-Mel-2, and SK-
Mel-28), as well as human melanocytes to a lesser
extent (Figure 2B).
Catalytically active SLT-1A
IYSNKLM triggers apoptosis in
human melanoma cells
The cytotoxic A subunit of SLT-1 inactivates protein
synthesis by depurinating an adenine residue (A4324)o n
28S rRNA and inducing apoptosis [15-19]. To confirm
that the toxicity for SLT-1A
IYSNKLM is in fact due to its
catalytic activity, a key residue (Y77) was mutated to a
serine within the A subunit of SLT-1, a substitution
known to inactivate wt SLT-1 [20]. Cell survival assays
indicated that 518-A2 cells are insensitive to the action
of the catalytically inactive form of SLT-1A
IYSNKLM (Fig-
ure 3A). In addition, 518-A2 cells exposed to SLT-
1A
IYSNKLM were shown to undergo apoptosis, as mea-
sured by the caspase-3 cleavage of a fluorescent peptide
Cheung et al. Molecular Cancer 2010, 9:28
http://www.molecular-cancer.com/content/9/1/28
Page 2 of 14substrate for this enzyme or by the cleavage of Poly
(ADP) ribose polymerase (PARP) (Figure 3B, C). In con-
trast, PC-3 cells were insensitive to the action of SLT-
1A
IYSNKLM (Figure 2A) and their exposure to this scRIP
resulted in only a modest level of caspase-3 activation
(Figure 3C).
SLT-1A
IYSNKLM binds to receptors on human melanoma
518-A2 cells
SLT-1A
IYSNKLM was radiolabeled with iodine-125 in
order to further assess its properties towards 518-A2
cells in vitro and later in vivo. The dissociation constant
of
125I-SLT-1A
IYSNKLM to receptors on human mela-
noma 518-A2 cells was derived at 4°C from a series of
competition binding curves. Specifically, 518-A2 cells
were incubated with
125I-SLT-1A
IYSNKLM ranging in
concentration from 1.2 × 10
-9 Mt o1 . 2×1 0
-6 Mi nt h e
presence (non-specific binding) and absence (total bind-
ing) of a 100-fold excess of unlabeled SLT-1A
IYSNKLM.
The equilibrium dissociation constant (K
a)f o r
125I-SLT-
1A
IYSNKLM was calculated to be 1.4 (± 0.2) × 10
-7 M
with 518-A2 human melanoma cells expressing 1.4 (±
0.1) × 10
5 binding sites for
125I-SLT-1A
IYSNKLM per cell
(Figure 4A). The binding of
125I-SLT-1A
IYSNKLM to 518-
A2 cells was also shown to be reversible. Displacement
binding curves of
125I-SLT-1A
IYSNKLM bound to 518-A2
cells with unlabeled SLT-1A
IYSNKLM defined its inhibi-
tory concentration (IC50) at 2.4 (± 0.3) × 10
-8 M (Figure
4B). Using this IC50 value, the dissociation constant (Kd)
of unlabeled SLT-1A
IYSNKLM was calculated to be 1.8 (±
0.3) × 10
-8 M (see Additional File 2: Supplementary
Text). The ten-fold increase in binding affinity for the
unlabeled form of SLT-1A
IYSNKLM in relation to its radi-
olabeled form (18 nM versus 140 nM) may reflect the
Figure 1 The scRIP SLT-1 A subunit served as a scaffold for the design and construction of an embedded 7-amino acid peptide
combinatorial SLT-1 A subunit library. (A) Schematic diagram of the SLT-1 A subunit. Furin cleavage occurs within its protease-sensitive loop
(C242 to C261) between residues 251 and 252 (FCS 251/252) of the A subunit [44]. A random 7-amino acid peptide library was inserted between
residues 245 and 246, generating cytotoxic A subunit variants with a surface-displayed library insert. Catalytic residues are shown in red. (B)
Modeled surface representations of the SLT-1 A subunit with and without a 7-residue long insertion. The models were derived from the crystal
structure of Shiga Toxin [45]. The peptide insertion (blue) is solvent-exposed and positioned away from residues involved in catalysis (residues
Y77, Y114, E167, R170, W203 colored in red) [20,46,47]. Models were rendered using PyMOL Software Version 1.0r1.
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nation is located in the 7-amino acid insert region. In
contrast, higher concentrations of the peptide,
HHHIYSNKLMASRVAR were needed to displace
bound
125I-SLT-1A
IYSNKLM from cells (Figure 4B). This
peptide corresponds to the sequence encompassing the
7-residue peptide binding domain of SLT-1A
IYSNKLM as
well as flanking residues within the A subunit. The cal-
culated Kd for this peptide was 1.4 (± 2.5) × 10
-6 M.
The peptide alone was thus more than 100-fold weaker
as a ligand than within the context of SLT-1A
IYSNKLM
suggesting that the tumor-targeting properties of SLT-
1A
IYSNKLM are imparted by both the inserted peptide
sequence and the SLT-1A scaffold.
SLT-1A
IYSNKLM rapidly localizes at tumor sites in vivo
In order to establish the in vivo properties of SLT-
1A
IYSNKLM, its stability was determined in human serum
at 37°C. No substantial level of protein degradation was
observed even after a 24 h exposure to 90% human
serum (see Additional File 4: Figure S3). SLT-1A
IYSNKLM
was also injected intravenously into groups of three
CD1 mice as a series of 5 consecutive (250 μg/kg; daily)
tail vein injections to assess antibody responses raised
against this mutant A subunit (Figure 5A). Only modest
IgG responses could be detected in three separate mice
as compared with CD1 mice that had subcutaneously
received the same antigen emulsified in Freund’sc o m -
plete adjuvant (Figure 5B). A representative set of IgG
responses as a function of mouse serum dilutions at day
42 post-injection is also presented in Figure 5C. Finally,
a tail vein injection of up to 4 mg/kg in mice did not
result in any signs of toxicity (results not shown). Over-
all, these findings suggest that the repeated injections of
SLT-1 A subunit variants such as SLT-1A
IYSNKLM elicit
modest humoral responses in mice and compare well
with responses observed in patients treated with other
targeted toxin therapies [21,22].
125I-SLT-1A
IYSNKLM was subsequently injected i.v. into
SCID mice bearing 518-A2 tumor xenografts [23] to
establish the pharmacokinetic parameters of this agent
and its ability to localize into tumor cells. The scRIP
was rapidly cleared through the kidneys with a circulat-
ing half-life (t1/2) of ~11 min, a value that is consistent
with a protein of this size (Figure 6A) [24]. Importantly,
the biodistribution profile showed marked tumor uptake
and retention of
125I-SLT-1A
IYSNKLM, reaching a maxi-
m u mo f~ 3 7 %i n j e c t e dd o s ep e rg r a mo ft u m o ra t1h
post-i.v. injection (Figure 6B). Tissue analyses also
demonstrated the selectivity of
125I-SLT-1A
IYSNKLM in
that tumor localization increases as the molecule is
Figure 2 Screening of the SLT-1 A subunit library yielded a
toxin variant, SLT-1A
IYSNKLM, displaying cytotoxicity towards
human melanoma cell lines. (A) Dose-response curves illustrating
the specific cytotoxicity of SLT-1A
IYSNKLM (black diamonds, black
triangles, black squares, black circles) compared to wt SLT-1A (white
diamonds, white triangles, white squares, white circles) for the 518-
A2 human melanoma cell line (black squares, white circles). The
carcinoma cell lines CAMA-1 (black diamonds, white diamonds;
human breast), HepG2 (black triangles, white triangles; human liver),
and PC-3 (black squares, white squares; human prostate) are
insensitive to SLT-1A
IYSNKLM. (B) Dose-response curves illustrating the
cytotoxicity profile of SLT-1A
IYSNKLM towards 8 different human
melanoma cell lines: 518-A2 (black circles), A-375 (black inverted
triangles), SK-Mel-28 (white circles), MeWo (black squares), A-2058
(white inverted triangles), MALME-3 M (white triangles), SK-Mel-2
(white squares), and C-32 (black triangles) as well as human
melanocytes (white diamonds). Error bars represent s.e.m. for
experiments performed in quadruplicate.
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and other tissues. Specifically, the tumor-to-blood ratios
of
125I-SLT-1A
IYSNKLM at 1 h, 6 h, 12 h, and 24 h post-
injection are 6.6, 3.1, 5.9 and 3.0 respectively.
To visualize the tumor-localization of SLT-1A
IYSNKLM,
a group of 518-A2 xenograft-bearing SCID mice
received a single i.v. injection of either
125I-SLT-
1A
IYSNKLM (900 μCi) or wt
125I-SLT-1A (900 μCi; nega-
tive control). The distribution of radiolabeled scRIPs
was recorded 45 min post-injection with a nanoSPECT/
CT scanner. The resulting CT MIP (Maximum Intensity
Projection) images were then overlaid with the SPECT
image slice that transversed the central plane of the
tumor (Figure 6C). These images highlight the rapid
localization and specificity of
125I-SLT-1A
IYSNKLM into
518-A2 cell xenografts as compared to the control, wt
125I-SLT-1A, which shows no tumor localization.
SLT-1A
IYSNKLM causes tumor regression and increased
survival in vivo
The final component in determining the usefulness of
SLT-1A
IYSNKLM was to assess the value of this scRIP in
improving the survival time of 518-A2 xenograft-bearing
SCID mice [23]. When tumors reached a volume of ~30
mm
3, animals received daily i.v. injections for ten days
of either saline, SLT-1A
IYSNKLM, or a 5-day i.p. regimen
of DTIC (a standard-of-care chemotherapeutic agent for
patients with advanced melanoma) or a combination
treatment involving both SLT-1A
IYSNKLM and DTIC.
Animal body weight, tumor volume and survival were
subsequently monitored over a period of 230 days (Fig-
ure 7). Body weight remained constant for all treatment
groups with no statistically significant amount of weight
loss being recorded during and after a treatment (Figure
7A). Tumor-bearing mice showed complete tumor
Figure 3 The cellular activities of SLT-1A
IYSNKLM are linked to its catalytic activity. (A) Dose-response curves indicating a comparable
cytotoxicity for the purified, furin-cleaved A subunit of SLT-1A
IYSNKLM (A1 and A2 subunits remain linked by a disulfide bridge between C242 and
C261; white squares) and the A1 subunit alone of SLT-1A
IYSNKLM (white circles) towards 518-A2 cells. The catalytically-inactive forms (Y77S) of
these same molecules (black squares, black circles) were not cytotoxic towards 518-A2 human melanoma cells at concentrations of up to 10 μM.
(B) Western blot analysis demonstrating the cleavage of PARP following treatment of 518-A2 cells with SLT-1A
IYSNKLM. (C) Effect of exposing 518-
A2 (black bars) and PC-3 cells (grey bars) to SLT-1A
IYSNKLM on the activation of caspase-3 as measured using a fluorescent peptide substrate for
caspase-3. PC-3 cells are insensitive to SLT-1A
IYSNKLM. Error bars represent s.e.m. for experiments performed in quadruplicate.
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IYSNKLM
leading to a statistically significant (P < 0.05) increase in
median survival from 40 days for the saline-treated
group to 47 days. This gain in survival was comparable
to the 46-day median survival observed for tumor-bear-
ing mice treated with DTIC alone (Figure 7B and 7C; P
= 0.86). The tumors eventually re-appeared following
the completion of the 10-day regimen with SLT-
1A
IYSNKLM (Figure 7C). In contrast, mice treated with
the combination of SLT-1A
IYSNKLM and DTIC demon-
strated an impressive median survival of 115 days,
shown to be statistically significant as assessed using the
Mantel-Cox test (P < 0.0001). This combination therapy
resulted in some mice demonstrating no tumour recur-
rence, suggesting that it is the result of marked additive
effects in combining therapies.
Discussion
The incidence of melanoma has been rapidly rising
worldwide with no effective treatment in sight for
patients with metastatic forms of this disease [1].
Despite decades of evaluating new therapeutic modal-
ities for advanced melanoma, patients are mainly being
treated with agents that display low response rates, i.e.
DTIC and IL-2 [2]. In view of the urgent need for new
therapeutic strategies, we designed and screened a com-
binatorial library based on the scaffold of a single chain
ribosome-inactivating protein (scRIP), namely the cyto-
toxic A subunit of SLT-1, to identify SLT-1 A variants
that target and kill human melanoma cells. In this
study, we demonstrated that the screening of this com-
binatorial SLT-1A protein library led to the identifica-
tion of a toxin variant termed SLT-1A
IYSNKLM that
selectively binds to human melanoma cells, is interna-
lized by them and results in their apoptotic death.
Immunotoxins derived from the fusion of the cyto-
toxic domain of Pseudomonas exotoxin A (PE) to a
tumor-targeted Fv fragment, have been shown to kill
cells using a combination of cytotoxic and cytostatic
mechanisms of action, namely the induction of apopto-
sis and cell death (cytotoxic mechanism) due to the
inhibition of protein synthesis (cytostatic effect) [25,26].
Wild type SLT-1 utilizes both mechanisms. Firstly, the
SLT-1 A subunit undergoes retrograde transport to the
endoplasmic reticulum, where it then retrotranslocates
to the cytoplasm and halts protein synthesis via its cata-
lytic activity by cleaving 28S rRNA [27]. The blockage
of protein synthesis subsequently triggers apoptosis
through the activation of caspases 8, 9, and 3 leading to
the display of morphological characteristics such as
membrane blebbing, DNA fragmentation, chromatin
condensation and cell shrinkage [14,17]. As presented in
Figure 3, only the catalytically active SLT-1A
IYSNKLM
kills cells, activates caspases-3 and cleaves PARP, as
observed for ricin, another common RIP family member
[28]. Thus, one key advantage of SLT-1A as a combina-
torial library template is that it yields small scRIP agents
with short new ligand binding domains without altering
the inherent intracellular localization and cytotoxic
properties of the A subunit. This mechanism of action
is distinct from most commonly prescribed anticancer
agents in the clinic, suggesting that the cytotoxic A sub-
unit of SLT-1 could complement the action of existing
drugs in combination therapy.
The melanoma-specific scRIP SLT-1A
IYSNKLM was
directly derived using RESCRIPT (Additional File 1: Fig-
ure S1) from a cell-based screen and its therapeutic
Figure 4 Binding of
125I-SLT-1A
IYSNKLM to 518-A2 cells.( A )
Specific binding (white squares), total binding (black squares), and
non-specific binding (white triangles) of
125I-SLT-1A
IYSNKLM to 518-A2
cells at 4°C. (B) Displacement curves in which 518-A2 cells were
treated with 45 nM of
125I-SLT-1A
IYSNKLM in the presence of
increasing concentrations of either unlabeled SLT-1A
IYSNKLM (black
circles) or a synthetic 16-residue peptide containing the inserted 7-
amino acid peptide ligand (HHHIYSNKLMASRVAR) (black squares).
Data points represent the s.e.m. of experiments performed in
triplicate.
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IYSNKLM generates modest IgG immune responses in CD1 mice. (A) Injection schedule of SLT-1A
IYSNKLM with and without
adjuvant. Treatments consisted of i.v. injections of SLT-1A
IYSNKLM prepared in saline into CD1 mice as a series of 5 consecutive (daily) tail vein
injections or a single s.c. injection of SLT-1A
IYSNKLM in Complete Freund’s adjuvant (CFA) followed by two s.c. boosts of the antigen in Incomplete
Freund’s adjuvant (IFA) at days 21 and 35. (B) Histogram illustrating the average IgG immune responses (1:1000 titer dilution) from 3 CD1 mice
injected with SLT-1A
IYSNKLM in the presence (black bars) or absence of adjuvant (white bars) as measured by ELISA at 405 nm. (C) Representative
IgG immune responses (average ELISA signals at 405 nm versus antisera titers; day 42) engendered for groups of three CD1 mice after injection
with SLT-1A
IYSNKLM in the presence (white circles) or absence of adjuvant (black circles). Data represent the s.e.m. of experiments performed in
triplicate.
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neer parts of its structure. This discovery and optimiza-
tion approach differs from preexisting immunotoxin
design strategies. Specifically, the traditional two-step
assembly of immunotoxins and related conjugates has
been based on an ap r i o r is e l e c t i o no fak n o w nt u m o r
marker. However, the fusion or chemical coupling of a
protein ligand (typically > 25 kDa) to a toxin domain
often generates large protein constructs displaying
altered functions in terms of cell targeting, cellular pro-
cessing and cytotoxic functions [9,22,29]. Secondly,
RESCRIPT, as a discovery to o l ,i sd i s t i n c tf r o mp h a g e
display approaches which are typically used to identify
peptide and protein ligands and are not presently com-
patible with cell killing assays. RESCRIPT thus limits
the need for post-discovery, protein engineering steps
required to ensure that functions such as cell targeting,
cellular routing and toxicity are retained by the resulting
conjugates.
Mechanistically, SLT-1A
IYSNKLM b e h a v e sa sac a t a l y t i -
cally active RIP causing apoptosis in 518-A2 melanoma
cells (Figure 3). SLT-1A
IYSNKLM was shown to bind to a
surface receptor on 518-A2 cells with a K
d of 18 nM.
These cells express about 140,000 copies of the receptor.
More importantly, the specific binding of this A subunit
variant to receptors on melanoma cells was rapid, satur-
able and reversible (Figure 4). Preliminary biochemical
studies aimed at determining the nature of the surface
determinant recognized by SLT-1A
IYSNKLM on 518-A2
melanoma cells, suggests that the receptor may not be a
protein. Specifically, pre-treating 518-A2 cells extensively
with trypsin yielded an identical SLT-1A
IYSNKLM cell cyto-
toxicity profile to that of untreated 518-A2 cells. Further-
more, preliminary cell surface radioiodination followed by
crosslinking/pull-down experiments with His-tagged SLT-
1A
IYSNKLM and wt SLT-1A did not reveal any unique radi-
olabeled membrane species that may act as putative SLT-
1A
IYSNKLM receptors on SDS-PAGE. Both approaches
Figure 6 In vivo blood clearance rate and tumor-targeting of
125I-SLT-1A
IYSNKLM (A) Blood clearance of
125I-SLT-1A
IYSNKLM shown as
percentage of injected dose per mL blood collected at various time points over a 72 h period post-i.v. injection. The clearance rate (t1/
2)o f
125I-SLT-1A
IYSNKLM was shown to be ~11 min. (B) Biodistribution per collected gram of wet tissue of
125I-SLT-1A
IYSNKLM after 1 h (black bars),
6 h (light grey bars), 12 h (dark grey bars) and 24 h (white bars) post-i.v. administration. (C) Tumor localization of
125I-SLT-1A
IYSNKLM versus wt
125I-
SLT-1A (negative control) as shown by nanoSPECT and CT imaging. The composite images show the tissue uptake of the radiolabeled proteins
(as pink colored areas) as well as the location of tumor xenografts (white circles) and that of kidneys (grey arrows).
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tivity. Biochemical and proteomic approaches are on-
going to define this melanoma-specific receptor. Studies
are also being conducted to determine whether the SLT-
1A
IYSNKLM receptor may be a cell-surface melanoma mar-
ker that has already been described in the literature.
Although several melanoma biomarkers have pre-
viously been reported, only a few are expressed on the
cell-surface and therefore would qualify as possible SLT-
1A
IYSNKLM receptor candidates [30]. These surface mar-
kers include HMW-MAA (high molecular weight mela-
noma associated antigen; melanoma chondroitin sulfate
proteoglycan; MCSP), S100B (originally known as S100),
CD44, CXCR4 (CXC chemokine receptor) and CEA-
CAM1 (carcinoembryonic-antigen-related cell adhesion
molecule 1) [31-37]. However, these known markers are
present on normal tissues as well as other cancer types,
highlighting challenges in designing melanoma-specific
therapies through the traditional method of conjugating
a ligand to a cell-killing component [30,33,36,38,39].
Nevertheless, antibodies raised against some of these
biomarkers, such as anti-Id mAb MK2-23 for HMW-
MAA, have shown promise in increasing patient survi-
val. To date, there is still a lack of clinically successful
melanoma-specific markers, and none for the detection
of primary tumors for high risk patients [30,40,41].
Figure 7 In vivo results following treatment regimens in SCID mice harboring established 518-A2 tumor xenografts. The regimens
included 10-day, daily injections of a saline control (i.v) (white circles) or SLT-1A
IYSNKLM (i.v. 0.5 mg/kg) (black circles), or a 5-day course of DTIC (i.
p. 8 mg/kg) (white squares), or the combination of both SLT-1A
IYSNKLM (i.v. 0.5 mg/kg) with DTIC (i.p. 8 mg/kg) regimens (black squares), (n = 7).
(A) Mice showed no change in body weight related to treatment regimens over time. (B) Measured tumor volumes of mice demonstrate a
significant synergistic effect of combining SLT-1A
IYSNKLM and DTIC treatments when compared to either treatment alone or to the saline control
(P < 0.0001). (C) Kaplan-Meier plot comparing animal survival as a function of treatment regimens (ten-day regimen; black bar).
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were also investigated in a mouse model and suggest
that the molecule is cleared with the expected half-life
profile of antibody fragments with a mass of ~30 kDa.
SLT-1A
IYSNKLM is also stable in human serum, displays
modest immunogenicity, and accumulates readily in
tumor xenografts of 518-A2 cells implanted in SCID
mice (Figure 6, Figure S4 and Figure 5 and 7). This
scRIP also retains its cytotoxic activity both in vitro (Fig-
ure 2 and 3) and in vivo as shown by the level of tumor
regression observed upon treating tumor-bearing mice
( F i g u r e7 ) .T h e s er e m a r k a b l ep r o p e r t i e ss u g g e s tt h a t
SLT-1A
IYSNKLM be pursued as a possible treatment
modality for melanoma patients displaying metastatic
forms of this disease.
Conclusions
We have developed and screened a combinatorial single
chain, ribosome-inactivating protein (scRIP) library with
a view to use the intrinsic cytotoxicity of all members of
the library (built-in search engine) as a tool to identify
melanoma-specific scRIP variants in the context of cell
viability assays. Library searches led to the discovery of
SLT-1A
IYSNKLM, a novel scRIP variant of the cytotoxic
A subunit of Shiga-like Toxin 1 that is able to target
and specifically kill human melanoma cells. SLT-
1A
IYSNKLM represents a candidate agent for treating
patients with metastatic melanoma.
Materials and methods
Antibodies, Cell Lines and Bacterial Strains
The 518-A2 human melanoma cell line was kindly pro-
vided by Dr. Burkhard Jansen [23] and maintained in
Dulbecco’s Modified Eagle Medium containing 5% FBS,
100 U/mL penicillin and 0.1 mg/mL streptomycin. All
other cell lines were purchased from ATCC and grown
according to company guidelines.
Library Design
Recombinant SLT-1A variants were generated using a
modified version of the method previously described by
our group [13]. The initial library was designed to vali-
date the variability of a heptapeptide insert as well as its
effect on SLT-1 A subunit cytotoxicity (see Additional
Files 2 and 3). The final heptapeptide library screened
was genetically inserted into the A subunit of His-tagged
SLT-1 between residues 245 and 246 by PCR. Specifi-
cally, the randomized insert was introduced by amplify-
ing a fragment of the SLT-1 gene using primers A
(CTG AAG CTT TAC GTT TTC GGC) and C (GAT
GCC ATT CTG GCA ACT CGC GAT GCS NNS NNS
NNS NNS NNS NNS NNS TGA TGA TGA CAA TTC
AGT ATT AAT GC). This product was ligated to the
remaining fragment, which had been amplified using
p r i m e r sB( G A GA C TG C AG A TT C CA T CT G T
TGG) and D (GCA TCG CGA GTT GCC AGA ATG
GCA), by PCR using primers A and B. After digestion
with HindIII and PstI, the resulting library cassette was
ligated into pECHE9A (pUC19-based plasmid that con-
stitutively expresses SLT-1 constructs in bacteria),
digested with NsiI to linearize wild-type material, trans-
formed and expressed in JM101 E. coli (Promega).
Expression and Purification of SLT-1A Subunit Library
Variants
Individual library colonies were picked from carbenicil-
lin-selective LB-agar plates and grown overnight at 37°C
in 1 mL of LB-broth in 96-well culture blocks. Bacterial
pellets were lysed in a single freeze-thaw cycle with
BugBuster Protein Extraction Reagent (Novagen) supple-
mented with 2.5 U/g pellet of Benzonase nuclease (EMD
Biosciences). Cleared lysates were transferred to 96-well
plates containing 2 μLo fN i - N T Am a g n e t i ca g a r o s e
beads (Promega) and incubated for 30 minutes at room
temperature. The beads were washed with Buffer A (50
mM phosphate buffer, pH 8, 300 mM NaCl, and 10
mM imidazole), and eluted with Buffer C (same as Buf-
fer A but with 250 mM imidazole). The generation of a
catalytically-inactive form of SLT-1A
IYSNKLM is
described in Additional File 2.
Large-Scale Protein Purification
JM101 E. coli (Promega) transformants of SLT-
1A
IYSNKLM (or the wt SLT-1A control) were grown in
LB-broth containing 100 μg/mL ampicillin with shaking
(225 rpm) at 37°C overnight. Each gram of cell pellet
was resuspended in 5 mL of BugBuster Reagent (Nova-
gen), 2.5 mL Buffer A (50 mM phosphate buffer, pH 8,
300 mM NaCl, and 10 mM imidazole), and 2.5 U Ben-
zonase (2.5 kU; Novagen), and an EDTA-free protease
inhibitor tablet (Roche). After stirring at room tempera-
ture for 1 h followed by centrifugation at 8,000 × g for
30 min, the cleared lysate was then loaded onto Ni-
NTA agarose (Sigma-Aldrich) pre-equilibrated with Buf-
fer A. The noncovalently-associated B subunit was
removed from the bound His-tagged A subunit by treat-
ing the column with 6 M guanidine-HCl in Buffer A.
The retained A subunits were renatured on the nickel
resin by washing with Buffer A containing decreasing
concentrations of guanidine-HCl [4.8 M, 3.6 M, 2.4 M,
and 1.2 M respectively]. After an additional wash with
Buffer B (50 mM phosphate buffer, 300 mM NaCl, 20
mM imidazole, pH 8), the purified A subunit was eluted
with Buffer C, concentrated and dialyzed against saline
using an Amicon ultrafiltration unit (Millipore; 10 kDa
MWCO). Proteolytic cleavage was achieved by incubat-
ing the purified A subunit with recombinant furin pro-
tease (New England Biolabs) in 100 mM MES buffer
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Typically, 1 mg of SLT-1 A subunit (or SLT-1A
IYSNKLM)
was cleaved with 10 U of furin for 48 h at 30°C. The
bacterial strains producing either wt SLT-1 or AB5 SLT-
1A
IYSNKLM typically led to the recovery of 7.5 (+/- 2.5)
mg of His-tagged purified toxins per liter of bacterial
medium. On average, 2 mg of purified, furin-digested
SLT-1A
IYSNKLM and 1.5 mg of purified, furin-digested
wt SLT-1A were obtained per liter of bacterial culture.
Samples were characterized by SDS-PAGE, and stained
w i t hC o o m a s s i eB l u e .T h ep u r i t yo ft h ef i n a lp r o d u c t s
was assessed by densitometry to be > 98% pure (See
Additional File 5; Figure S4).
Cell Viability and Apoptosis Measurements
Cells were exposed to escalating concentrations of puri-
fied SLT-1A
IYSNKLM or purified scRIP library variants
for 1 h at 37°C followed by a 48 h incubation period in
fresh medium. The viability of adherent cells was subse-
quently determined using the sulforhodamine B assay
[42]. Apoptosis as measured by the activation of caspase
3 was determined after treating cells with 1 μMS L T -
1A
IYSNKLM f o r6h .C a s p a s e3p r o t e o l y t i ca c t i v i t yw a s
assessed via the cleavage of the peptide substrate Ac-
DEVD-AFC (SensoLyte Homogeneous AFC caspase-3/7
assay kit; ANASPEC) and of PARP [43] by immunoblot-
ting with a rabbit polyclonal antibody to human ARP
(Cell Signaling Technology).
125I Radiolabeling and Radioligand Binding Assays
SLT-1A
IYSNKLM and SLT-1A subunits were radioiodi-
nated with carrier-free Na
125I (37 MBq/10 uL; MP Bio)
and Iodogen (Pierce). Radiolabeled A subunits were pur-
ified from unincorporated
125I by gel permeation (D-Salt
Polyacrylamide, Pierce) and the specific activity deter-
mined and counted in a Wallac Wizard 3” 1480 instru-
ment (PerkinElmer). The specific activity obtained was
2.1 × 10
17 cpm/mol and 7.1 × 10
16 cpm/mol for the
SLT-1A
IYSNKLM and wt SLT-1A subunits respectively.
Data was plotted and analyzed using GraphPad Prism
5.0 (GraphPad Software, Inc). Details regarding radioli-
gand binding assays are available in Additional File 2.
Pharmacokinetic, Biodistribution, Immunogenicity and
Imaging Studies
Human melanoma 518-A2 cells (4 × 10
6 cells suspended
in 0.2 mL culture medium) were implanted subcuta-
neously into five-week-old female SCID mice [23],
resulting in tumor xenografts (volume of ~30 mm
3)
within 14 days. For pharmacokinetic analyses, tumor-
bearing mice received a single i.v. injection of either
125I-SLT-1A
IYSNKLM or wt
125I-SLT-1A (14 μg, 150 μl
dose in USP grade saline; 100 μCi). Blood samples were
collected via the saphenous vein and counted in a
gamma counter to determine blood clearance rates (4
mice per group). For biodistribution studies, a separate
group of tumor-bearing SCID mice was anesthetized
using 5% isoflurane gas and blood samples collected via
cardiac puncture. Mice were sacrificed and tissues col-
lected, weighed and counted in a gamma counter (n =
4). Results were reported as percent injected dose per
gram of wet tissue weight.
Immunogenicity studies were performed with CD1
mice (3 mice per time point) given a series of 5 conse-
cutive (250 μg/kg; 100 μLd a i l y )i . v .i n j e c t i o n so fS L T -
1A
IYSNKLM prepared in saline to mimic the therapeutic
treatment procedure. As a positive control, a single dose
(250 μg/kg; 100 μL) of this A chain emulsified (1:1) in
Complete Freund’sa d j u v a n t( C F A )w a si n j e c t e ds u b c u -
taneously into CD1 mice (control group). The control
animals also received s.c. injections of the same antigen
emulsified (1:1) in Incomplete Freund’sa d j u v a n t( I F A ;
250 μg/kg; 100 μL dose) at day 21 and 35. To assess
IgG immune responses raised against SLT-1A
IYSNKLM,
blood samples were collected at various time intervals
post-injection (day 1, 10, 15, 21, 35, 42 for SLT-
1A
IYSNKLM; day 21, 35, 42 for the antigen with adju-
vant). IgG responses were titrated for each mouse by
serially diluting serum samples and measuring IgG levels
by ELISA in 96-well plates pre-coated with 100 ng of
SLT-1A
IYSNKLM. Serum-treated wells (in triplicate) were
subsequently exposed to an HRP-conjugated goat-anti-
mouse IgG (1:1000) and ELISA signals recorded with a
plate reader at 405 nm using the substrate ABTS (2,2’-
Azinobis [3-ethylbenzothiazoline-6-sulfonic acid]-dia-
mmonium salt).
Imaging experiments were carried out at the UHN
STTARR facility using a dual-modality NanoSPECT/CT
(Bioscan) and are further described under Additional
File 2 (2 mice). All animal protocols were reviewed and
approved by the Animal Care Committee at the Univer-
sity Health Network.
Tumor Regression Studies
The effects of SLT-1A
IYSNKLM and DTIC treatment on
t h es u r v i v a lo f5 1 8 - A 2t u m o r - b e a r i n gS C I Dm i c e[ 2 3 ]
were assessed when tumor xenografts reached a volume
of ~30 mm
3. At this stage, animals received daily i.v.
injections of either saline, SLT-1A
IYSNKLM (0.5 mg/kg;
Days 8 to 12 and 15 to 19) or an i.p. dose of DTIC (8
mg/kg; Days 8 to 12) or the combination treatment of
both SLT-1A
IYSNKLM (i.v. dose: 0.5 mg/kg; Days 8 to 12
and 15 to 19) and DTIC (i.p. dose: 8 mg/kg; Days 8 to
12) (7 mice per treatment regimen). Mice were weighed
and the dimension of their tumors measured with cali-
pers. Tumor volumes were calculated by assuming a
prolate spheroid shape (tumour volume = (large dia-
meter × [short diameter]
2)/2). Animal survival was
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nized by exposure to CO2 when tumor diameters
reached 15 mm, or when ulcerations or other signs of
distress such as poor grooming were observed in accor-
dance with the regulatory parameters of the Animal
Care Committee at the University Health Network.
Statistical Analysis
Statistical analyses of tumor growth in mice were per-
formed using one-way analysis of variance (ANOVA).
Kaplan-Meier curves were used to summarize the distri-
bution of mouse survival times. We used the Mantel-
Cox test to compare the survival curves among treat-
ment groups. All statistical tests were performed using
GraphPad Prism 5.0 (GraphPad Software, Inc). P values
less than 0.05 were considered statistically significant.
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Additional file 1: Figure S1: RESCRIPT: A discovery tool for the
Rapid Evolution and Selection of Cancer-Specific Ribosome-
Inactivating Protein Toxins. Diagram outlining the general procedure
for the screening and identification of Shiga-like Toxin 1 (SLT-1) A
subunit toxin variants with novel cancer-targeting and killing properties.
His-tagged toxin variants were individually purified and applied to 96-
well plates seeded with cancer cell lines. Cell viability was assessed using
a sulforhodamine B (SRB) assay [24].
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-28-
S1.TIFF]
Additional file 2: Supplementary Text
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-28-
S2.DOC]
Additional file 3: Figure S2: The catalytic function of the SLT-1 A
subunit was not disrupted by inserting a 7-residue peptide
between residues 245 and 246. (A) The heptapeptide insert did not
affect the ribosome-inactivating activity of the purified toxin variants
compared to the wt A subunit as measured by the biosynthesis of
luciferase (relative light units) in a coupled transcription/translation assay.
Legend: wt SLT-1 (open squares), SLT-1A
PDTRPAP (open triangles), and a
catalytically-inactive SLT-1 variant bearing E167A and R170A mutations
within the A subunit (open circles). The peptide insert within the context
of the toxin A subunit is exposed and recognized by large proteins such
as antibodies. Samples were probed with either an anti-SLT-1 A subunit
polyclonal antisera or a PDTRPAP-specific anti-Onc-M27 monoclonal
antibody. (B) Western blot analyses of purified A and A1 subunits for wt
SLT-1 or SLT-1A
PDTRPAP. (C) ELISA experiments comparing the
immunoreactivity of purified AB5, A and A1 subunits to the Onc-M27
mAb for wt SLT-1 and SLT-1A
PDTRPAP toxins.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-28-
S3.TIFF]
Additional file 4: Figure S3: Serum stability of SLT-1A
IYSNKLM.
Western blot analysis demonstrating the serum stability of SLT-1A
IYSNKLM
at 37°C over a period of 24 h.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-28-
S4.TIFF]
Additional file 5: Figure S4: Purified SLT-1A
IYSNKLM. Coomassie-
stained, SDS-PAGE gel showing Lane 1) purified SLT-1A
IYSNKLM before
furin digestion; Lane 2) purified SLT-1A
IYSNKLM after furin treatment; 3)
purified wt SLT-1A before furin digestion; Lane 4) purified wt SLT-1A after
furin treatment.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-28-
S5.TIFF]
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